What is the main business of Polfarmex?

The main business activity of Polfarmex focuses on manufacture of pharmaceutical preparations.

When was the company founded?

The company was registered in the Polish National Court Register (KRS) on April 20, 2004.

Where is the headquarters located?

The headquarters is located at: Józefów 9, 99-300 Kutno.

Who is on the management board?

The management board includes Marek Piotr Wośko (President of the Management Board).

What is the share capital?

The share capital of the company is PLN 7,006,340 (approx. $1.9 million).

What period do the latest financial data cover?

The latest available financial statement covers the period from January 1, 2024 to December 31, 2024.

What revenue was generated?

In 2024, the company generated total revenue of $65,418,137, representing a decrease of 4.7% compared to 2023.

No, the company recorded a net loss of $1,519,041 in 2024. For comparison, in 2023 the loss was $679,391, meaning the company increased its loss by 112.4%.

Which cost dominates operating expenses?

The largest operating cost category falls under materials and energy. This category amounted to $21,561,190 in 2024, representing 37% of all operating expenses.

PolfarmexS.A.

Manufacture of pharmaceutical preparations

KRS: NIP: REGON:

Overview

Status

Active

Registry date

2004-04-20

Share capital

7 006 340,00 PLN

Activity description

Polfarmex is a Polish manufacturer of generic medications that has been providing high-quality, affordable, and safe pharmacological therapies for 35 years. The company offers prescription and over-the-counter drugs, dietary supplements, and cosmetics, with 80% of its products developed in-house. Polfarmex operates in 15 foreign markets, expanding its presence in Europe and beyond.

Registered address

Józefów 9, 99-300 Kutno, Poland

Website

polfarmex.pl

Phone

Social media

Electronic delivery address

AE:PL-29451-11218-ABGBT-15

Financials

Revenue history (in m)

Data and insights are generated automatically based on financial statements and may contain errors. This analysis is for informational purposes only and does not constitute an official assessment of the company's credibility or business advice.

Statistics

How the company ranks by revenue within its industry, region and across Poland in 2025.

Results vs industry

Revenue

This companyUSD 73.54mMedianUSD 816.16kAverageUSD 29.28m

Net profit

This companyUSD -140.80kMedianUSD 8.96kAverageUSD 2.64m

Operating costs

This companyUSD 60.58mMedianUSD 701.47kAverageUSD 19.26m

Assets

This companyUSD 117.79mMedianUSD 800.13kAverageUSD 29.34m

News

2025-07-22

Employee Safety as an Investment by Polfarmex

2025-05-06

Treatment of Lung Diseases is Our Priority

2024-07-17

Polfarmex Products with the Status of "Polish Medicine"

2024-06-20

5000 PLN from Polfarmex for Research on Compounds with Anticancer Properties

2023-11-21

Together Against Antibiotic Resistance

2023-11-11

Polfarmex Rises in Prestigious Ranking

Industry

Bank accounts

Registered as a VAT taxpayer on 1993-07-05. Active

ING Bank Śląski
03 1050 1461 1000 0090 3018 2571
mBank
09 1140 1108 0000 3778 8900 1002
BNP Paribas Bank Polska
30 2030 0045 1110 0000 0059 6600

Debt

No entries in the National Debtors Register (KRZ). No proceedings in KRZ

MSiG notices

Publication date	Event
Jan 26, 2022	Commercial Companies Code notice
May 23, 2016	Merger plan
Aug 5, 2015	Transformation registered

Public aid

20 public aid cases recorded, with a total value of $2,102,857.

Grant date	Purpose	Gross amount	Granting body
Sep 13, 2024	De minimis aid (in accordance with Commission Regulation 2023/2831)	$26,061$26,061	Certes sp. z o.o.
May 27, 2024	De minimis aid (in accordance with Commission Regulation 2023/2831)	$10,905$10,905	Starosta Powiatu Kutnowskiego
Jan 19, 2023	Aid for research and development projects: experimental development	$400.2K$400,150	Prezes Agencji Badań Medycznych

Tenders

No recorded participation in tenders.

Regulatory authorisations

Authority	Type	Status
BDO	Waste generation	Active
BDO	Integrated permit	Active

Authorized Representatives

Bogdan Szczepan Manowski — Vice President of the Management Board

Jarosław Kazimierz Walczak — Management Board Member

Marek Piotr Wośko — President of the Management Board

Manner of representation

Authorised to make declarations of will on behalf of the company are: 1) the President of the Management Board independently; 2) two members of the management board acting jointly; 3) a member of the management board acting jointly with a commercial proxy.

Supervisory board

Melania Anna Podziewska — Supervisory Board Member

Wojciech Cezary Wośko — Supervisory Board Member

Katarzyna Elżbieta Wośko — Supervisory Board Member

Iwona Szadkowska — Supervisory Board Member

Magdalena Kossakowska — Supervisory Board Member

Beneficial owners

Person	Rights
Marek Piotr Wośko (61)	Shareholder of a joint-stock company, 52.0%

Subsidiaries

Name	Share value	Stake
Media Arrksp. z o.o.	84,548.89 USD	61.0136%
Ośrodek Badań Farmaceutycznych i Klinicznych Biofanasp. z o.o.	28,363.05 USD	46.6667%
Drive Technologiessp. z o.o.	310.64 USD	23%

Competitors

Name	Revenue	Website
Anpharm Przedsiębiorstwo FarmaceutyczneS.A.	$111,469,394.21	anpharm.pl
Przedsiębiorstwo Produkcji Farmaceutycznej Hasco - LekS.A.	$119,621,017.71	hasco-lek.pl
Delpharm PoznańS.A.	$110,900,246.81	delpharm.com
Tarchomińskie Zakłady Farmaceutyczne PolfaS.A.	$102,988,448.02	polfa-tarchomin.com.pl
ICN Polfa RzeszówS.A.	$85,044,250.03	icnpolfa.pl
Wrocławskie Zakłady Zielarskie HerbapolS.A.	$46,537,868.51	herbapol.pl
Phytopharm KlękaS.A.	$46,154,888.31	phytopharm.pl
Instytut Biotechnologii Surowic i Szczepionek Biomed - Skrót Firmy Ibss BiomedS.A.	$37,103,878.54	biomed.pl
Poznańskie Zakłady Zielarskie HerbapolS.A.	$31,668,225.77	herbapol.poznan.pl
VipharmS.A.	$30,660,173.61	vipharm.pl

Change history

Date	Event
2015-03-05	Share capital change (7,000,000.00 PLN → 7,006,340.00 PLN)
2015-03-05	PKD change (Removed: 10.86.Z, 10.89.Z, 18, 20.14.Z, 20.41.Z, 20.59.Z, 41.10.Z, 41.20.Z, 46.18.Z, 46.38.Z, 46.39.Z, 46.75.Z, 47.74.Z, 47.75.Z, 55.10.Z, 56.10.A, 68.10.Z, 68.20.Z, 73, 77.32.Z, 85.59.B, 86.90.E)
2014-10-29	PKD change (Added: 77.12.Z)
2011-08-31	PKD change (Added: 46.38.Z, 46.39.Z)
2010-08-31	PKD change (Removed: 15.88.Z, 15.89.Z, 24.14.Z, 24.41.Z, 24.42.Z, 24.51.Z, 24.52.Z, 24.66.Z, 25.22.Z, 45.21.A, 51.18.Z, 51.45.Z, 51.46.Z, 51.55.Z, 52.31.Z, 52.32.Z, 52.33.Z, 55.11.Z, 55.12.Z, 55.30.A, 70.11.Z, 70.12.Z, 70.20.Z, 71.32.Z, 73.10.F, 74.13.Z, 74.40.Z, 80.42.B, 85.14; Added: 10.86.Z, 10.89.Z, 18, 20.14.Z, 20.41.Z, 20.42.Z, 20.59.Z, 21.10.Z, 21.20.Z, 41.10.Z, 41.20.Z, 46.18.Z, 46.45.Z, 46.46.Z, 46.75.Z, 47.73.Z, 47.74.Z, 47.75.Z, 55.10.Z, 56.10.A, 68.10.Z, 68.20.Z, 72.19.Z, 73, 73.20.Z, 77.32.Z, 85.59.B, 86.90.E)

FAQ

Last updated: 2026-07-16